Analysis is first to compare health system-based electronic health record data for treatment of pulmonary embolism with interventional devices MARLBOROUGH, Mass., Oct. 24, 2023 /PRNewswire/ -- Data ...

Princess U. Ogbogu, Division Chief of Pediatric Allergy, Immunology, and Rheumatology at University Hospitals Rainbow Babies and Children’s Hospital and Case Western Reserve University, Cleveland, OH, ...

Quince Therapeutics (QNCX) rated Buy ahead of Phase 3 NEAT readout in A-T; eDSP targets $1B+ orphan market with strong cash ...

Positive full results from the Phase III TULIP-SC trial showed the subcutaneous administration of Saphnelo demonstrated a statistically ...

In the intent to treat analysis, Dermata saw statistically significant differences in IGA treatment success, inflammatory lesion count, and non-inflammatory lesion count at week 4 (earliest measured ...

CAMBRIDGE, Mass., July 1, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NRSN) (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe ...

Change from baseline at day 56 (week eight) in tear production (Schirmer’s test). Change from baseline at day 56 in ocular symptoms measured by OSDI score. The study also met secondary endpoints, ...

The MarketWatch News Department was not involved in the creation of this content. -- Full results from REGEN-007 are being held and will be submitted to the American Society of Nephrology 2025 Kidney ...

Analysis is first to compare health system-based electronic health record data for treatment of pulmonary embolism with interventional devices Each year, approximately 350,000 patients in the United ...